+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

United States Anesthesia Drugs Market, By Type [General Inhalation Anesthesia, General Intravenous Anesthesia and Local Anesthesia], Companies

  • ID: 4577468
  • Report
  • June 2018
  • Region: United States
  • 136 Pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie
  • Baxter International Inc
  • Endo International plc
  • MORE

Anesthesia is a medicine which is given to relieve pain and sensation during surgery. Drugs render a patient unresponsive and unconscious. United States Anesthesia Drugs Market is projected to reach US$ 5 Billion by the year 2024 owing to the increasing prevalence of cardiovascular cases, rising geriatric population and growing number of urgent surgeries in the United States. The different types of anesthesia are Local Anesthesia, General Inhalation Anesthesia and General Intravenous Anesthesia. Local Anesthesia and General Anesthesia are the two commonly used types of anesthesia. Local anesthesia is a condition when sensation within a specific body part in inhibited, where as general anesthesia results in loss of consciousness and sensation. Furthermore, the public and private health insurers’ consideration of adding anesthetic products in their reimbursement policy is expected to boost the US anesthesia drugs market in the recent years.

All Major Companies Losing their Market Share

In United States all established companies are losing their market share. Primarily because anesthesia drugs are mostly sold in generic form as it is available in the low cost. The companies studied in the report are Baxter International Inc,  Endo International plc & AbbVie. Today, with the help of anesthesia medical facilities, performs various surgeries to treat patient’s deformities in the field of trauma, cardiovascular, gastrointestinal, urological, orthopedics, ophthalmology, neurology, oncology and cosmetics.

The report titled “United States Anesthesia Drugs Market, By Type [General Inhalation Anesthesia, General Intravenous Anesthesia (Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate & Fentanyl) and Local Anesthesia (Articaine, Bupivacaine, Lidocaine, Mepivacaine & Prilocaine], Companies (Baxter International, Endo International plc, AbbVie & Others)” provides a complete analysis of United States Anesthesia Drugs Market.

By Type – General Intravenous Anesthesia leads the Market but Local Anesthesia Drugs is the Future

The report studies the market of the following Anesthesia Drugs segments: General Inhalation Anesthesia, General Intravenous Anesthesia can be further subdivided into (Propofol, Benzodiazepines Class, Fospropofol Disodium, Ketamine, Methohexital Sodium, Pentobarbital, Etomidate & Fentanyl),  Among these anesthesia, Propofol and Benzodiazepines Class are the leading anesthesia drugs. Local Anesthesia is further segmented into (Articaine, Bupivacaine, Lidocaine, Mepivacaine & Prilocaine). Among these Articaine and Lidocaine have good market share.   
 
Companies Analysis

Baxter International, Endo International plc, and AbbVie are some of the top companies operating in the United States Anesthesia Drugs Market; which has been studied thoroughly in the report.

This market research report provides a complete analysis of the United States Anesthesia Drugs Market and their projections for the upcoming years, Growth Drivers, Challenges, and Reimbursement policy. 

By Type - United States Anesthesia Drugs Market

  •  General Inhalation Anesthesia
  •  General Intravenous Anesthesia
    • Propofol
    • Benzodiazepines Class
    • Fospropofol Disodium
    • Ketamine
    • Methohexital Sodium
    • Pentobarbital
    • Etomidate
    • Fentanyl
  •  Local Anesthesia
    • Articaine
    • Bupivacaine
    • Lidocaine
    • Mepivacaine
    • Prilocaine

Key Players Sales - United States Anesthetic Drugs Market

  • Baxter International Inc
  • Endo International plc
  • AbbVie

This Report provides the answer of following Questions:

  • What will be the United States Anesthesia Drugs Market by 2024?
  • What will be the United States Local Anesthesia Drugs Market for the year 2024?
  • What was the United States General Inhalation Anesthesia Drugs Market in 2017?
  • Among General Inhalation, General Intravenous and Local Anesthesia; which one is driving the United States Anesthesia Drugs Market?
  • What are the key driving forces for United States Anesthesia Drugs Market?
  • What are the key challenges to United States Anesthesia Drugs Market?
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Baxter International Inc
  • Endo International plc
  • MORE

1. Executive Summary

2. United States Anesthesia Drugs Market

3. Market Share – United States Anesthesia Drugs
3.1 Anesthesia Drugs
3.2 General Intravenous Anesthesia Drugs
3.3 Local Anesthesia Drugs
3.4 Company

4. Market – United States Anesthesia Drugs Types
4.1 General Inhalation Anesthesia Drugs Market
4.2 General Intravenous Anesthesia Drugs Market
4.3 Local Anesthesia Drugs Market

5. Market – General Intravenous Anesthesia Drugs
5.1 Propofol
5.2 Benzodiazepines Class (Diazepam and Midazolam)
5.3 Fospropofol Disodium
5.4 Ketamine
5.5 Methohexital Sodium
5.6 Pentobarbital
5.7 Etomidate
5.8 Fentanyl

6. Market – Local Anesthesia Drugs
6.1 Articaine
6.2 Bupivacaine
6.3 Lidocaine
6.4 Mepivacaine
6.5 Prilocaine

7. Companies - United States Anesthesia Drugs Market
7.1 Baxter International Inc. Anesthesia Drugs Sales
7.2 Endo International plc Anesthesia Drugs Sales
7.3 AbbVie Anesthesia Drugs Sales
7.4 Other Companies Anesthetic Drugs Sales

8. Merger & Acquisition (M&A) – United States Anesthesia

9. Reimbursement Policy - Private Health Insurance Providers
9.1 Aetna International
9.2 Coventry Health Care
9.3 Anthem Blue Cross and Blue Shield
9.4 Blue Cross and Blue Shield of Texas
9.5 UnitedHealthcare
9.5.1 State Exceptions

10. Reimbursement Policy – Public Health Insurance Providers
10.1 Medicare
10.2 MDWise

11. Growth Drivers
11.1 Growing Demand for Anesthesia Service
11.2 Rise in Ageing Population & Prevalence of Cardiovascular Disease in United States

12. Challenges
12.1 Un-match Anesthesia Providers in United States
12.2 Shortage of Anesthesia Drugs in United States

List of Figures:
Figure 2-1: United States – Anesthesia Drugs Market (Million US$), 2011 – 2017
Figure 2-2: United States – Forecast for Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 3-1: United States – Anesthesia Drugs Market Share by Type (Percent), 2011 – 2017
Figure 3-2: United States – Forecast for Anesthesia Drugs Market Share by Type (Percent), 2018 – 2024
Figure 3-3: United States – General Intravenous Anesthesia Drugs Market Share (Percent), 2011 – 2017
Figure 3-4: United States – Forecast for General Intravenous Anesthesia Drugs Market Share (Percent), 2018 – 2024
Figure 3-5: United States – Local Anesthesia Drugs Market Share (Percent), 2011 – 2017
Figure 3-6: United States – Forecast for Local Anesthesia Drugs Market Share (Percent), 2018 – 2024
Figure 3-7: United States – Anesthesia Drugs Market Share by Company (Percent), 2011 – 2017
Figure 3-8: United States – Forecast for Anesthesia Drugs Market Share by Company (Percent), 2018 – 2024
Figure 4-1: United States – General Inhalation Anesthesia Drugs Market (Million US$), 2011-2017
Figure 4-2: United States – Forecast for General Inhalation Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 4-3: United States – General Intravenous Anesthesia Drugs Market (Million US$), 2011 – 2017
Figure 4-4: United States – Forecast for General Intravenous Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 4-5: United States – Local Anesthesia Drugs Market (Million US$), 2011-2017
Figure 4-6: United States – Forecast for Local Anesthesia Drugs Market (Million US$), 2018 – 2024
Figure 5-1: United States – Propofol Market (Million US$), 2011 – 2017
Figure 5-2: United States – Forecast for Propofol Market (Million US$), 2018 – 2024
Figure 5-3: United States – Benzodiazepines Class Market (Million US$), 2011 – 2017
Figure 5-4: United States – Forecast for Benzodiazepines Class Market (Million US$), 2018 – 2024
Figure 5-5: United States – Fospropofol Disodium Market (Million US$), 2011 – 2017
Figure 5-6: United States – Forecast for Fospropofol Disodium Market (Million US$), 2018 – 2024
Figure 5-7: United States – Ketamine Market (Million US$), 2011 – 2017
Figure 5-8: United States – Forecast for Ketamine Market (Million US$), 2018 – 2024
Figure 5-9: United States – Methohexital Sodium Market (Million US$), 2011 – 2017
Figure 5-10: United States – Forecast for Methohexital Sodium Market (Million US$), 2018 – 2024
Figure 5-11: United States – Pentobarbital Market (Million US$), 2011 – 2017
Figure 5-12: United States – Forecast for Pentobarbital Market (Million US$), 2018 – 2024
Figure 5-13: United States – Etomidate Market (Million US$), 2011 – 2017
Figure 5-14: United States – Forecast for Etomidate Market (Million US$), 2018 – 2024
Figure 5-15: United States – Fentanyl Market (Million US$), 2011 – 2017
Figure 5-16: United States – Forecast for Fentanyl Market (Million US$), 2018 – 2024
Figure 6-1: United States – Articaine Market (Million US$), 2011-2017
Figure 6-2: United States – Forecast for Articaine Market (Million US$), 2018 – 2024
Figure 6-3: United States – Bupivacaine Market (Million US$), 2011-2017
Figure 6-4: United States – Forecast for Bupivacaine Market (Million US$), 2018 – 2024
Figure 6-5: United States – Lidocaine Market (Million US$), 2011-2017
Figure 6-6: United States – Forecast for Lidocaine Market (Million US$), 2018 – 2024
Figure 6-7: United States – Mepivacaine Market (Million US$), 2011-2017
Figure 6-8: United States – Forecast for Mepivacaine Market (Million US$), 2018 – 2024
Figure 6-9: United States – Prilocaine Market (Million US$), 2011-2017
Figure 6-10: United States – Forecast for Prilocaine Market (Million US$), 2018 – 2024
Figure 7-1: United States – Baxter International Anesthesia Drugs Sales (Million US$), 2011-2017
Figure 7-2: United States – Forecast for Baxter International Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 7-3: United States – Endo International plc Anesthesia Drugs Sales (Million US$), 2011-2017
Figure 7-4: United States – Forecast for Endo International plc Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 7-5: United States – AbbVie Anesthesia Drugs Sales (Million US$), 2011 - 2017
Figure 7-6: United States – Forecast for AbbVie Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 7-7: United States – Other Companies Anesthesia Drugs Sales (Million US$), 2011 – 2017
Figure 7-8: United States – Forecast for Other Companies Anesthesia Drugs Sales (Million US$), 2018 – 2024
Figure 11-1: United States – Cosmetic Procedures (Number), 1997, 2012-2013, 2015-2016
Figure 11-2: United States – Ageing Population by Age Group (Thousand), 2012 – 2016
Figure 12-1: United States – By Region Availability of Anesthesia Specialists (Percent), 2010
Figure 12-2: United States – By States Availability of Anesthesia Specialists (Percent), 2010
Figure 12-3: United States – Drugs Shortage (Number), 2001-2015
Figure 12-4: United States – Anesthesia Drugs Shortage with the Highest Frequency (Percent), 2012

List of Tables:
Table 8-1: United States – Anesthesia Market Merger & Acquisitions (M&A), Jan 2016 – March 2017
Table 9-1: Coventry Health Care - Anesthesia Modifiers, 2016
Table 9-2: Blue Cross and Blue Shield of Texas - Physical Status Modifiers, 2017
Table 9-3: Blue Cross and Blue Shield of Texas - Qualifying Circumstances, 2017
Table 9-4: Blue Cross and Blue Shield of Texas - Modifier Information Billed by an Anesthesiologist, 2017
Table 9-5: Blue Cross and Blue Shield of Texas - Modifier Information Billed by a CRNA, 2017
Table 9-6: Blue Cross and Blue Shield of Texas - Anesthesia Modifier Reimbursement
Table 9-7: UnitedHealthcare Community – Modifiers, 2017
Table 10-1: Medicare - Reimbursement Formulas
Table 10-2: Medicare - General and Monitored Anesthesia Care
Table 10-3: Medicare - Anesthesia Modifiers, 2017
Table 10-4: MDwise –Type of Service & PA Requirement
Table 10-5: MDwise - Anesthesia Time Table, 2017
Table 10-6: MDwise - Qualifying Circumstances, 2017
Table 10-7: MDwise - Status Modifiers, 2017
Table 11-1: United States – Cardiovascular Disease Prevalence (Percent), 2010,2015,2020,2025, 2030

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Baxter International Inc
  • Endo International plc
  • AbbVie
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll